{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 49,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/16",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.78,
        "y": 0.33
      },
      "kind": "chart",
      "text": "High Transduction Efficiency comparison",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d665f991-ca17-4669-8b4f-9ddc50cfccb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.78,
        "y": 0.53
      },
      "kind": "chart",
      "text": "Low Tonic Signaling ELISA results",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0dcdb19-1fe6-4e7c-843a-590fd6d24223",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.78,
        "y": 0.73
      },
      "kind": "chart",
      "text": "Anti-Exhaustion Capability flow cytometry histograms",
      "attrs": null,
      "subkind": "histogram",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65ab3bf8-f290-49c8-bd99-f9e6c1ffef2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.04,
        "y": 0.3
      },
      "kind": "image",
      "text": "Mechanism of action diagram showing BCMA cancer cell and NXC-201 CAR-T cell interaction",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cb77d75-5a0e-402e-af18-4f2e507948a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.43,
        "x": 0.02,
        "y": 0.74
      },
      "kind": "list",
      "text": "NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) produced by our N-GENIUS platform targeting B-cell maturation antigen (BCMA). High Overall Response Rates in AL Amyloidosis and Multiple Myeloma. First Outpatient CAR-T: Short CRS duration (median 2 days) starting on day 0. No Neurotoxicity, only 1 grade 3 CRS across 42 Multiple Myeloma patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0838553e-4851-473d-9414-522b6b4d3405",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.02,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89e8e058-d3df-4911-b2ad-f5cdec27a3cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.17,
        "y": 0.18
      },
      "kind": "title",
      "text": "NXC-201: FIRST BCMA CAR-T GENERATED BY THE N-GENIUS PLATFORM",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "24899d20-daf2-4f93-bcce-8edeaa96ccf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "NXC-201 MoA: Next Generation CAR-T For Multiple Myeloma and AL Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49dd8c1c-de9b-4194-9081-e6d07b9fd2bc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 8,
      "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
      "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
      "position": 0,
      "objective": "Highlighting the need for improved therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}